Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk

Grants

Funding Acknowledgements

On behalf of the Pancreatic Cancer Case-Control and Cohort Consortia, we would like to acknowledge the critical role Dr. Gloria Petersen played in the establishment and ongoing success of the consortium, including the early stages of this study. Gloria was a friend, colleague, and mentor to those in the pancreatic cancer research community and beyond, and her legacy continues through these consortia. This work was supported by U01CA247283, R01CA154823, and P50CA062924 (PI: A.P. Klein) and the Intramural Research Program, Division of Cancer Epidemiology and Genetics, NCI (PI: R.Z. Stolzenberg-Solomon). The IARC/Central Europe study was supported by a grant from the NCI at the NIH (R03 CA123546-02) and grants from the Ministry of Health of the Czech Republic (NR 9029-4/2006, NR9422-3, NR9998-3, and MH CZ-DRO-MMCI 00209805) The work at Johns Hopkins University was supported by the NCI grants P50CA062924 and R01CA97075. Additional support was provided by the Lustgarten Foundation; Susan Wojcicki and Dennis Troper; and the Sol Goldman Pancreas Cancer Research Center. This work was supported by RO1 CA154823 and federal funds from the NCI, NIH, under contract number HHSN261200800001E. The Mayo Clinic Biospecimen Resource for Pancreas Research study is supported by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701). The Queensland Pancreatic Cancer Study was supported by a grant from the National Health and Medical Research Council of Australia (NHMRC; grant number 442302). R.E. Neale is supported by a NHMRC Senior Research Fellowship (#1060183). The UCSF pancreas study was supported by NIH-NCI grants (R01CA1009767, R01CA109767-S1, and R0CA059706) and the Joan Rombauer Pancreatic Cancer Fund. Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program; the NCI's Surveillance, Epidemiology, and End Results Program under contract HSN261201000140C awarded to CPIC; and the CDC's National Program of Cancer Registries, under agreement #U58DP003862-01 awarded to the California Department of Public Health. The Yale (CT) pancreas cancer study is supported by NCI at NIH, grant 5R01CA098870. The cooperation of 30 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged. The Connecticut Pancreas Cancer Study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in that study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of the data obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study II cohort. The authors express sincere appreciation to all Cancer Prevention Study II participants and to each member of the study and biospecimen management group. The authors would like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries and cancer registries supported by the NCI's Surveillance, Epidemiology, and End Results Program. Cancer incidence data for CLUE were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene, Baltimore, MD http://phpa.dhmh.maryland.gov/cancer. We thank the state of Maryland, the Maryland Cigarette Restitution Fund, and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that support the collection and availability of the cancer registry data. We thank all the CLUE participants. Melbourne Collaborative Cohort Study (MCCS) cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further augmented by NHMRC grants 209057, 396414, and 1074383 and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database. The NYU study (A. Zeleniuch-Jacquotte and A.A. Arslan) was funded by NIH R01 CA098661 and UM1 CA182934 and center grants P30 CA016087 and P30 ES000260. The Physicians' Health Study was supported by research grants CA-097193, CA-34944, CA-40360, HL-26490, and HL-34595 from the NIH, Bethesda, MD. The Women's Health Study was supported by research grants CA182913, CA-047988, HL-043851, HL-080467, and HL-099355 from the NIH. Health Professionals Follow-up Study is supported by NIH grant UM1 CA167552. from the NCI, Bethesda, MD. Nurses' Health Study is supported by NIH grants UM1 CA186107, P01 CA87969, and R01 CA49449 from the NCI. Additional support from the Hale Center for Pancreatic Cancer Research, U01 CA21017 from NCI, and the United States Department of Defense CA130288, Lustgarten Foundation, Pancreatic Cancer Action Network, Noble Effort Fund, Peter R. Leavitt Family Fund, Wexler Family Fund, and Promises for Purple was provided to B.M. Wolpin. The Shanghai Men's Health Study is supported by NIH grant UM1CA173640. The Shanghai Women's Health Study is supported by NIH grant UM1CA182910. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, US Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The authors thank the WHI investigators and staff for their dedication and the study participants for making the program possible. A full listing of WHI investigators can be found at http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf. The SELECT study is supported by NIH grant award numbers U10 CA37429 (C.D. Blanke) and UM1 CA182883 (C.M. Tangen and I.M. Thompson). The authors thank the site investigators and staff and, most importantly, the participants from PCPT and SELECT who donated their time to this trial. The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1, MC-UU_12015/1, and MC_UU_00006/1) and Cancer Research UK (C864/A14136). We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the NIH, (http://biowulf.nih.gov).